Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag

Main Article Content

Rajakrishnan Vijayakrishnan *
Sourbha Dani
Aparna Ramasubramanian
Rekha Nair
Tony M. Samaha
(*) Corresponding Author:
Rajakrishnan Vijayakrishnan | vrajakrishnan@gmail.com

Abstract

HIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.

Downloads month by month

Downloads

Download data is not yet available.

Article Details